Association of HER2 Expression with Clinical, Endoscopic, and Histopathological Features in Gastric Adenocarcinoma

Authors

  • dr. Virly Nanda Muzellina, SpPD, K-GEH

DOI:

https://doi.org/10.24871/2722026107-110

Abstract

-

References

Caniparoli A, Saenz Briones P, Rezzonico andBarg RAJS. Gastric Cancer. Rev Argent Cir. 2024 Oct 28;26(6):127–8. doi:10.1201/b22898-58. PubMed PMID: 29083746.

Ramachandran R, Grantham T, Parvataneni S, Budh D, Gollapalli S, Reddy M, et al. Gastric Cancer: Clinical Features, Screening, Diagnosis, Treatment, and Prevention. J Community Hosp Intern Med Perspect. 2024 Mar 1;14(2):49. doi:10.55729/2000-9666.1304. PubMed PMID: 38966500.

Pous A, Notario L, Hierro C, Layos L, Bugés C. HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies. Int J Mol Sci. 2023 Jul 1;24(14). doi:10.3390/IJMS241411403. PubMed PMID: 37511163.

Cetin B, Ozet A. HER2/neu as target in gastric adenocarcinoma. Transl Gastroenterol Hepatol. 2016;1(JULY):59. doi:10.21037/TGH.2016.06.08. PubMed PMID: 28138626.

Ma C, Wang X, Guo J, Yang B, Li Y. Challenges and future of HER2-positive gastric cancer therapy. Front Oncol. 2023 Jan 30;13:1080990. doi:10.3389/FONC.2023.1080990/XML.

Ratti M, Citterio C, Orlandi E, Vecchia S, Anselmi E, Toscani I, et al. Fighting HER2 in Gastric Cancer: Current Approaches and Future Landscapes. International Journal of Molecular Sciences. 2025 Jul 28;26(15):7285. doi:10.3390/IJMS26157285. PubMed PMID: 40806416.

Lucas FAM, Cristovam SN. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016 May 21;22(19):4619. doi:10.3748/WJG.V22.I19.4619. PubMed PMID: 27217694.

Boku N. HER2-positive gastric cancer. Gastric Cancer. 2013 Jan;17(1):1. doi:10.1007/S10120-013-0252-Z. PubMed PMID: 23563986.

B A V, Behera MK, Patne SCU, Shukla SK, Dixit VK. Clinicopathological Significance and Prognostic Role of Her2neu Protein Expression in Patients with Carcinoma Stomach: A Prospective Study from Northern India. South Asian J Cancer. 2023;12(2):135. doi:10.1055/S-0042-1759601. PubMed PMID: 37969677.

Larasati D. Hubungan Gambaran Klinis, Endoskopi, Histopatologi terhadap Ekspresi HER2 dan Kesintasan Dua Tahun pada Adenokarsinoma Gaster [Internet]. 2021 [cited 2026 Aug 24]. Available from: //perpus.internafkui.or.id%2Findex.php%3Fp%3Dshow_detail%26id%3D978.

Aditi R, Aarathi R, Pradeep R, Hemalatha L, Akshatha C, Amar K. HER2 Expression in Gastric Adenocarcinoma—a Study in a Tertiary Care Centre in South India. Indian J Surg Oncol. 2015 Mar 1;7(1):18. doi:10.1007/S13193-015-0436-6. PubMed PMID: 27065677.

Jung K, Park MI, Kim SE, Park SJ. Borrmann Type 4 Advanced Gastric Cancer: Focus on the Development of Scirrhous Gastric Cancer. Clin Endosc. 2016 Jul 1;49(4):336. doi:10.5946/CE.2016.057. PubMed PMID: 27456608.

Nho LV, Van Huy T, Cong Thuan Đ, To T Van. Endoscopy, histopathological findings and HER2 overespression in gastric adenocarcinoma. Journal of Medicine and Pharmacy. 02(1).

Sarkar RN, Ravutu L, Jagadev S, Sumanlatha GR, Polisetty SR, Lakshmi CV. Histopathological Analysis and HER‐2/neu Expression in Endoscopic Guided Upper Gastrointestinal Biopsies: An Observational Study. Research Journal of Medical Sciences. 2023;17(11):166–72. doi:10.59218/makrjms.2023.11.166.172.

Jørgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer. 2012;3(1):137–44. doi:10.7150/JCA.4090. PubMed PMID: 22481979.

Downloads

Published

2026-08-31

How to Cite

Muzellina, SpPD, K-GEH, dr. V. N. (2026). Association of HER2 Expression with Clinical, Endoscopic, and Histopathological Features in Gastric Adenocarcinoma. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 27(2), 107–110. https://doi.org/10.24871/2722026107-110

Issue

Vol. 27 No. 2 (2026): VOLUME 27, NUMBER 2, August, 2026

Section

Editorial

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).